Patents deal
Innovectis, the technology transfer company of Johann Wolfgang Goethe University, Frankfurt, has sold a family of patents and and patent applications to regenerative therapeutics company t2cure.
The company, which develops novel progenitor cell-based regenerative therapeutics, is closely connected to the university already – its pipeline is built on clinical studies there by the founders
According to PR Newswire, t2cure will use its technology for potency testing to confirm product specifications in the course of its upcoming pivotal Phase III study in acute myocardial infarction. This study, which will enrol up to 1,400 patients, is scheduled to enroll its first patients in the second quarter of 200
“This acquisition of patent rights is a significant contribution to our regulatory strategy, as our lead product is advancing into a pivotal Phase III study in acute myocardial infarction,” said Manfred Ruediger, CEO of t2cure. “These patent rights complement our existing IP portfolio, supporting our commitment to make stem cell-based therapeutics a clinical reality for patients suffering from an acute heart attack or chronic heart failure.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
